BioCentury
ARTICLE | Clinical News

Adipiplon: Phase II/III halted

July 21, 2008 7:00 AM UTC

Neurogen suspended a double-blind, placebo-controlled, crossover U.S. Phase II/III trial comparing 6 mg and 9 mg of oral adipiplon to placebo or 12.5 mg Ambien CR after adipiplon showed a higher-than...